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Reactive Oxygen Species in Tumor Necrosis
Factor-a-Activated Primary Human Keratinocytes:
Implications for Psoriasis and Inflammatory Skin
Disease
Chen N. Young1,4, Jay I. Koepke2, Laura J. Terlecky2,3, Michael S. Borkin1, Savoy L. Boyd1 and
Stanley R. Terlecky3
The multifunctional cytokine tumor necrosis factor-a (TNF-a) is known to play an important role in
inflammatory and immunological responses in human skin. Although it has been documented that reactive
oxygen species (ROS) are involved in TNF-a-induced signaling pathways associated with certain inflammatory
diseases, their role in TNF-a signaling cascades has not been examined in primary human keratinocytes used as
a model of inflammatory skin disease and psoriasis. Employing a series of in vitro and in cellulo approaches, we
have demonstrated that in primary human keratinocytes (i) TNF-a rapidly induces ROS generation, IkB
degradation, NF-kB p65 nuclear translocation, and ultimately production of inflammatory cytokines; (ii) TNF-a-
induced cytokine production is mediated both by the mammalian target of rapamycin signaling pathway via
NF-kB activation and by ROS; (iii) TNF-a-dependent NF-kB activation (that is, IkB degradation and NF-kB p65
nuclear translocation) is not mediated by ROS; and (iv) a cell-penetrating derivative of the antioxidant enzyme,
catalase, as well as taurine and N-acetyl-cysteine attenuate the TNF-a-induced production of cytokines. These
latter results suggest that catalase and perhaps other antioxidants should be considered as part of a more
specific and effective therapy for the treatment of inflammatory skin diseases, including psoriasis.
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INTRODUCTION
Skin, the outermost layer of the body, is the largest human
organ. It plays an important protective role by providing an
interactive boundary between the body and the environment.
Skin is repeatedly exposed to ionizing and UV radiation and
systemically introduced to potentially toxic dietary and drug
metabolites, all of which may influence its health and
appearance (Sander et al., 2004). Many of these environ-
mental agents and endogenous metabolites are natural
oxidants. They can directly or indirectly drive the production
of a variety of reactive oxygen species (ROS) through a
number of physiological processes (Kohen, 1999; Trouba
et al., 2002). The surface of the skin is especially sensitive
to ROS. Many studies have documented their role in skin
aging, the development of inflammatory skin disorders, and
carcinogenesis (Briganti and Picardo, 2003; Sander et al.,
2004; Okayama, 2005).
One particular skin pathology, psoriasis, is an incurable
disorder that has been defined as a chronic inflammatory
disease largely mediated by immune cells (Nickoloff
and Nestle, 2004). Although it affects 2–4% of the general
population worldwide, its etiology remains largely unknown.
However, it can be triggered by stress or trauma, and
by bacterial, fungal, or viral infection of the skin (Krueger,
2002; Lebwohl, 2003). Psoriasis is generally characterized
by hyperproliferation, abnormal differentiation, and altered
maturation of the epidermis, as well as inflammation in
the epidermis and dermis (Banno et al., 2004; Chamian
and Krueger, 2004). The pathogenesis of psoriasis has
been reported to be driven by activated T cells or antigen-
presenting cells, which release a number of cytokines and
chemokines. These then bind to surface receptors and signal
keratinocytes to hyperproliferate and abnormally differenti-
ate. This, in turn, causes the accumulation of additional
cytokines and inflammatory mediators in the lesional skin
(Barker, 1991; Nickoloff, 2001; Gudjonsson et al., 2004).
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Tumor necrosis factor-a (TNF-a) is a major mediator in the
pathogenesis of psoriasis. It is a multifunctional cytokine that
is believed to play an important role in mediating inflamma-
tion, immune responses, and apoptosis (Tracey and Cerami,
1994; Aggarwal and Natarajan, 1996; Locksley et al., 2001).
It has been reported that there are much higher levels of TNF-
a found in the skin of patients with psoriatic lesions as
compared to that of normal subjects (Mease, 2004; De Rycke
et al., 2005; Veale et al., 2005). In addition to TNF-a, other
inflammatory cytokines and a transcription factor, NF-kB, are
found to be highly expressed in psoriatic patients (Bachelez,
2005). One of the molecular mechanisms proposed is that
TNF-a produced locally within psoriatic lesions causes NF-
kB activation, subsequently leading to increased expression
of other cytokines as well as of TNF-a itself. Thus, the view is
that a TNF-a-NF-kB activation-increased TNF-a/inflam-
matory cytokine expression positive feedback loop exists that
maintains and may enhance the inflammatory process within
psoriatic plaques (Barnes and Karin, 1997; Bachelez, 2005;
Punzi et al., 2007). A number of studies support the proposed
importance of TNF-a-positive feedback loops in the patho-
physiology of psoriasis (Mease, 2005; Nash and Florin, 2005;
Saripalli and Gaspari, 2005). However, there is also the
speculation that increased ROS production and deficient
function of cellular antioxidant systems play a critical role in
the etiology of the disease (Antille et al., 2002; Briganti and
Picardo, 2003). Importantly, these points have yet to be
examined in a cell model of inflammatory skin disease,
specifically primary human keratinocytes treated with TNF-a.
Although the extent to which keratinocytes themselves
contribute to the TNF-a load seen in psoriatic skin remains a
matter of some debate, these cells can clearly produce the
cytokine and other inflammatory mediators (for example, see
Johansen et al., 2006), and therefore a molecular analysis of
the underlying mechanisms of such production is clearly
warranted. The overall aim of this study was to investigate, in
primary human keratinocytes, the role of ROS in psoriasis-
associated TNF-a signaling cascades. We show that treatment
with TNF-a (i) stimulates ROS generation; (ii) activates NF-kB
signaling through IkB degradation and NF-kB p65 nuclear
translocation; and (iii) increases mRNA expression of the
cytokines, IL-8, IL-6, and TNF-a itself. We implicate the
serine/threonine protein kinase, mammalian target of rapa-
mycin (mTOR), in these processes and also show that
quenching hydrogen peroxide and downstream ROS with a
cell-penetrating catalase derivative or other antioxidants is an
effective means of reducing inflammatory cytokine gene
expression. Taken together, these results shed light on the
biochemistry and pathophysiology of inflammatory skin
diseases, including psoriasis, at the level of the keratinocyte,
and may provide previously unknown targets for therapeutic
intervention.
RESULTS
TNF-a treatment induces hydrogen peroxide/ROS generation
To evaluate whether or not cellular hydrogen peroxide
production was involved in TNF-a-mediated signaling, we
measured levels of the ROS produced in primary human
keratinocytes. First, we found that treatment with TNF-a
caused a time-dependent increase in hydrogen peroxide
production; this occurred within 5minutes of TNF-a stimula-
tion and reached a maximum at approximately 20minutes
(Figure 1). Having identified a ‘‘threshold time’’ (B20min-
utes), we addressed ROS production in a dose–response
analysis (Figure 2). We found that TNF-a increases ROS
production in a dose-dependent (0–100 ngml1) manner.
These findings correlate well with results showing TNF-a-
induced ROS generation in other human cell types (Schulze-
Osthoff et al., 1992; Goossens et al., 1995) as well as in
canine keratinocytes (Kohler et al., 2001). However, to the
best of our knowledge, we are the first group to demonstrate
these phenomena in primary human keratinocytes.
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Figure 1. Time course of hydrogen peroxide production induced by TNF-a in
primary human keratinocytes. Cells (2 105ml1) were treated with
10 ngml1 TNF-a for the indicated times. The amount of hydrogen peroxide
produced in cells was determined using oxidation of the fluorogenic indicator
Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine). Fluorescence units data
presented reflect subtraction of untreated control cell values and are the
means±SEM of triplicate samples. Similar results were seen in two additional
experiments.
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Figure 2. Dose response of hydrogen peroxide production induced by TNF-a
in primary human keratinocytes. Cells (2 105ml1) were treated with
varying amounts of TNF-a (from 0 to1,000 ngml1) for 20minutes, and the
amount of hydrogen peroxide produced in cells was determined as in
Figure 1. Results presented are the means±SEM of triplicate samples. Similar
results were seen in two additional experiments.
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TNF-a stimulates NF-jB activation in human primary
keratinocytes
The NF-kB is a ubiquitous transcription factor for genes
encoding proinflammatory and inflammatory cytokines,
chemokines, and growth factors (Liou and Baltimore, 1993;
Baldwin, 1996; Ghosh and Karin, 2002; Takao et al., 2003).
In resting cells, IkB forms a complex with NF-kB that masks
the nuclear localization sequences of NF-kB and thus
prevents it from entering the nucleus. Upon cell stimulation,
for example after TNF-a treatment, IkB proteins are rapidly
phosphorylated and degraded by the proteasome pathway,
and the newly freed NF-kB molecule translocates into the
nucleus to activate expression of the multiple target genes
noted above. The phosphorylation and degradation of IkB are
thus the important steps in the pathway leading to NF-kB
activation.
To assess activation of NF-kB following TNF-a exposure,
we examined IkB degradation and NF-kB nuclear transloca-
tion as the relevant parameters. IkB degradation was
evaluated by western blot analysis using an anti-IkBa
antibody. Our results show that degradation of IkBa induced
by TNF-a occurs very rapidly, with some 70% of the
molecule being lost in the first 15minutes (Figure 3). Next,
we studied the effect of TNF-a on nuclear translocation of the
NF-kB p65 subunit. To accomplish this, we performed laser
scanning indirect immunofluorescence confocal microscopy
using an antibody to the p65 molecule. As shown in Figure 4,
the immunofluorescence staining pattern showed quite
clearly the translocation of p65 into the nucleus of human
keratinocytes after treatment with TNF-a. As expected, this
molecule remained in the cytoplasm of untreated control
cells.
Induction of TNF-a, IL-8, and IL-6 mRNA expression following
TNF-a stimulation
Although it has been well documented that high concentra-
tions of TNF-a are present in skin lesions of patients with
psoriasis (Mease, 2004; De Rycke et al., 2005; Veale et al.,
2005), to date the effect of TNF-a on cytokine expression in
primary human keratinocytes has not been determined. To
address this point, we examined whether or not TNF-a is able
to increase the (mRNA) expression of itself or other potent
inflammatory cytokines in primary human (cultured) kerati-
nocytes. We performed real-time reverse transcriptase-PCR
(RT-PCR) (Figure 5) and found that in response to TNF-a, the
message levels for TNF-a, IL-8, and IL-6 were all significantly
increased. For IL-6, this induction was nearly 40-fold as
compared to untreated controls (Figure 5).
Role of the mTOR pathway in TNF-a-induced cytokine
upregulation
mTOR is, as mentioned above, a conserved serine/threonine
protein kinase and a member of the cellular phosphatidyl-
inositol 3-kinase/AKT pathway. We investigated its role in
NF-kB activation and ROS production induced by TNF-a by
using rapamycin (sirolimus), a well-characterized immuno-
suppressant and potent inhibitor of the signaling cascade. As
described above, the phosphorylation and subsequent
degradation of IkB play a critical role in regulating NF-kB
translocation to the nucleus and subsequent transcriptional
regulation. In Figure 6, we asked if rapamycin has any effect
on TNF-a-induced degradation of IkBa; clearly, it did. IkBa is
largely stabilized by the pretreatment.
Furthermore, we showed that rapamycin inhibits mRNA
expression of TNF-a, IL-8, and IL-6 (Figure 5). These results
support the notion that there is a connection between the
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Figure 3. Degradation of IjB(a) induced by TNF-a in primary human
keratinocytes. Cells (2 106ml1) were treated with 10 ngml1 TNF-a for the
indicated times, and cell lysates were prepared as described in Materials and
Methods. (a) Western blot analysis of IkBa or tubulin using appropriate
polyclonal antibodies. (b) Densitometric analysis of the immunoreactive
bands obtained after western blotting. Results are presented as IkBa/tubulin
normalized ratios. Similar results were seen in duplicate experiments.
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Figure 4. Nuclear translocation of the NF-jB p65 subunit induced by TNF-a
in primary human keratinocytes. Cells were stimulated with TNF-a
(10 ngml1) for 1 hour. Nuclear translocation of the NF-kB p65 subunit was
assessed by indirect immunofluorescence confocal microscopy using
anti-p65 subunit antibodies and appropriate fluorescently tagged secondary
antibodies. A representative image of several obtained is included here.
Bar¼10 mm. Similar results were seen in duplicate experiments.
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mTOR signaling cascade, NF-kB activation, and inflamma-
tory cytokine expression. Importantly, such a link between
mTOR and NF-kB has already been put forth (Ghosh et al.,
2006), and is supported by our observations.
Finally, our analysis of the mTOR pathway showed that
rapamycin has only modest effects on TNF-a-induced ROS
production in these cells (Figure 7). One interpretation of
these results is that ROS production lies upstream of the
mTOR to NF-kB signaling cascades in TNF-a-activated
primary human keratinocytes.
Involvement of ROS in TNF-a signaling in primary human
keratinocytes
The results presented thus far have demonstrated that in
primary human keratinocytes, treatment with TNF-a rapidly
induces ROS generation, activation of the mTOR and NF-kB
signaling and transcription pathways, and mRNA expression
of the proinflammatory cytokines TNF-a, IL-8, and IL-6. We
next asked what the effects of TNF-a would be on cells
pretreated with a targeted antioxidant. To analyze this point,
we employed a transducible form of catalase as a specific
ROS scavenger that efficiently decomposes hydrogen per-
oxide. This genetically engineered catalase molecule (here-
after called Cat*) is modified with a cell-penetrating peptide
(specifically, an arginine nonamer) at its amino terminus and
a high efficiency peroxisomal targeting signal 1 (specifically,
serine–lysine–leucine) at its carboxy terminus. This enzyme
rapidly enters cells and efficiently traffics to the peroxisome
to metabolize hydrogen peroxide. The strategy of restoring or
supplementing peroxisomal catalase in cells has been shown
to re-establish oxidative balance, to renew mitochondrial
integrity (by repolarizing the organelle), and to delay
senescence (Wood et al., 2006; Koepke et al., 2007; Terlecky
and Koepke, 2007). Our results indicate that Cat* prophylaxis
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Figure 6. Effects of rapamycin on TNF-a-induced IjB degradation in primary
human keratinocytes. Cells (2 106ml1) were pretreated or not with
rapamycin (20 nM) for 1 hour and then challenged with 10 ngml1 TNF-a for
30minutes. (a) Western blot analysis, and (b) densitometric measurements
and normalization of IkBa and tubulin levels were performed as outlined in
Figure 3. Similar results were seen in duplicate experiments.
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Figure 7. Effects of rapamycin and antioxidants on hydrogen peroxide
production induced by TNF-a in primary human keratinocytes. Cells
(2105ml1) were pretreated or not with rapamycin (Rap) (20 nM), catalase
(Cat*) (1 mM), taurine (Taur) (40mM), or N-acetyl-cysteine (NAC) (5mM) for
1 hour and then challenged with TNF-a (10 ngml1) for 30minutes. Hydrogen
peroxide production was measured using DCF-DA as outlined in Materials
and Methods. Fluorescence unit data presented reflect subtraction of
untreated control cells values and are the means of triplicate samples. Similar
results were seen in two additional experiments.
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Figure 5. Effects of TNF-a and rapamycin on expression of TNF-a, IL-8, and
IL-6. Primary human keratinocytes were treated with TNF-a (10 ngml1) for
6 hours. Total RNA was then isolated and mRNA analysis performed by
real-time RT-PCR. Where indicated, cells were pretreated with rapamycin
(20 nM) for 1 hour and then challenged with TNF-a. Data are expressed
as fold induction of relevant mRNAs as compared to untreated controls.
Representative results (means±SEM) from one of three independent
experiments are shown.
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significantly reduces the amount of hydrogen peroxide and
related ROS present in TNF-a-treated keratinocytes (Figure 7).
Furthermore, these cells are unable to induce expression of
TNF-a mRNA to the level seen in non-antioxidant pretreated
cells (Figure 8).
Importantly, similar results were seen with taurine, a
sulfur-containing b-amino acid, and N-acetyl cysteine, the
acetylated precursor of both L-cysteine and reduced glu-
tathione (Figures 7 and 8). Both molecules possess antiox-
idant properties and elicit a variety of effects on cells (Petty
et al., 1990; Huxtable, 1992; Atmaca, 1998). Taurine’s
demonstrated ability to control release of proinflammatory
cytokines in a number of organisms is consistent with the
effects seen in Figure 8.
The obvious suggestion is that hydrogen peroxide and
related ROS are stimulating expression of inflammatory
cytokines in this model system. To further test this, cells
were pretreated with hydrogen peroxide directly or with 3-
aminotriazole, a specific inhibitor of catalase. In both cases,
the resultant oxidative load present in cells enhanced TNF-a’s
ability to induce cytokine expression (Figure 8).
We next asked if activation of NF-kB in response to TNF-a
was mediated by ROS. This does not appear to be the case, as
cells pretreated with Cat*, taurine, or N-acetyl-cysteine still
degrade IkB(a) in response to TNF-a (Figure 9). Therefore,
even though ROS certainly plays a role in the expression of
inflammatory cytokines induced by TNF-a, it apparently is
not through IkB degradation and accompanying NF-kB
activation/nuclear translocation. Rather, it appears that there
exists a redox-independent IkB degradation/NF-kB activation
step involved in TNF-a-activated primary human keratino-
cytes.
DISCUSSION
The pathogenesis of psoriasis is still not completely understood.
It is certainly a disease of immune cells with some, as yet to be
clearly defined, contribution by skin cells including keratino-
cytes. Collectively, these cells conspire to potentiate the
development of chronic skin inflammation through the
production of cytokines (Bhalerao and Bowcock, 1998;
Krueger et al., 2001; Krueger, 2002; Lebwohl, 2003; Nickoloff
and Nestle, 2004; Albanesi et al., 2005). Among these is TNF-
a, the major proinflammatory cytokine of psoriasis, which
activates cells in a positive feedback loop producing other
inflammatory mediators, including ROS and various other
cytokines (Gottlieb et al., 2005; Lowes et al., 2005; Pelle et al.,
2005). It is also thought that an insufficient antioxidant system,
together with increased levels of ROS, contributes to the
pathogenesis (Antille et al., 2002; Briganti and Picardo, 2003;
Baz et al., 2003; Bickers and Athar, 2006).
One aim of this work was to gain a better understanding of
the interactions between TNF-a, ROS, and antioxidants in the
initiation and progression of the disease. Our studies
employing primary human keratinocytes clearly support a
role for ROS in TNF-a-induced cytokine expression. We
demonstrate rapid TNF-a-dependent ROS generation (Figures
1 and 2). In addition, we show that quenching the resultant
oxidative stress with either a cell-penetrating, peroxisomally
targeted, catalase derivative or the antioxidants taurine or
N-acetyl-cysteine significantly reduces the accompanying
elevated cytokine expression (Figure 8). The suggestion is that
disturbances in the oxidant–antioxidant system in human skin
may play an important role in the pathogenesis of psoriasis.
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Figure 8. Effect of hydrogen peroxide on TNF-a-induced gene expression
in primary human keratinocytes. Cells were pretreated or not with
3-aminotriazole (3-AT) (1 mM), hydrogen peroxide (2.5 mM), catalase (Cat*)
(1 mM), taurine (Taur) (40mM), or N-acetyl-cysteine (NAC) (5mM) for 1 hour
and then challenged with TNF-a (10 ngml1) for 6 hours. Total RNA was then
isolated and TNF-a mRNA analysis performed by real-time RT-PCR. Data are
expressed as fold induction of relevant mRNAs as compared to untreated
controls. Representative results (means±SEM) from one of three independent
experiments are shown.
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Figure 9. Effects of antioxidants on TNF-a-induced IjB degradation in
primary human keratinocytes. Cells (2 106ml1) were pretreated or not
with catalase (Cat*) (1 mM), taurine (Taur) (40mM), N-acetyl-cysteine (NAC)
(5mM) for 1 hour and subsequently challenged with TNF-a (10 ngml1) for
30minutes. (a) Western blot analysis, and (b) densitometric measurements
and normalization of IkBa and tubulin levels were performed as outlined in
Figure 3. Similar results were seen in duplicate experiments.
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As current systemic medications for psoriasis have been
reported to have significant side effects, we propose that
targeted antioxidant prophylaxis, akin to the strategy em-
ployed here with a transducible catalase derivative, is worth
considering as a potential treatment modality.
Our results also implicate the critical cellular kinase,
mTOR, in response to TNF-a. This enzyme participates in,
and often regulates, a variety of cellular functions, including
protein synthesis and autophagy, as well as (cell) growth,
survival, and proliferation (Hay and Sonenberg, 2004; Inoki
et al., 2005; Ghosh et al., 2006). The molecule and
associated complex partners integrate a variety of upstream
signals and modulate a number of downstream effectors.
Perhaps best underscoring the importance of mTOR and
interaction complex members is the now well-established
role of these molecules, when dysregulated, in cancer
(Tokunaga et al., 2004; Tsang et al., 2007). In primary
human keratinocytes treated with TNF-a, mTOR appears to
regulate NF-kB activation (Figure 6). Interestingly, (inhibiting)
mTOR has little effect on TNF-a’s ability to elicit ROS
formation (Figure 7), suggesting that distinct mechanisms are
at work. Therefore, TNF-a’s stimulation of inflammatory
cytokine expression employs both mTOR-dependent and
mTOR-independent reactions.
Considering NF-kB activation further, it was unexpected
that quenching TNF-a-induced ROS did not inhibit the
process (Figure 9). Indeed, IkBa was degraded (and thus
NF-kB activated) as well or better in the presence of the
antioxidant. At first glance, this seemed inconsistent with a
number of observations in other cellular contexts, suggesting
a role for ROS in NF-kB activation (Schreck et al., 1991;
Bubici et al., 2006; Gloire et al., 2006; Nakano et al., 2006).
Although the answer is not completely clear, we speculate
that perhaps NF-kB-induced transcription of relevant genes is
redox sensitive. Therefore, the ROS-requiring step lies
downstream of NF-kB activation. Further experimentation
will be required to confirm this conjecture.
In summary, our findings suggest a rather straightforward
series of biochemical relationships. In primary human
keratinocytes, TNF-a induces ROS, stimulates mTOR, and
activates NF-kB, resulting in expression of inflammatory
cytokines. What should not be lost is that the pathways may
interact or may function independently. The intricacy
presumably reflects the complexity of psoriasis and related
inflammatory skin diseases. Having identified some of the
relevant pathways in the overall response of human primary
keratinocytes to TNF-a, a more careful dissection of specific
components and underlying molecular mechanisms may
now begin.
MATERIALS AND METHODS
Reagents and antibodies
TNF-a was obtained from R&D Systems (Minneapolis, MN). DMEM/
F12, fetal bovine serum, trypsin–EDTA, phosphate-buffered saline
(PBS), and other products for cell culture were supplied by Invitrogen
(Carlsbad, CA). Serum-free culture EpiLife Medium and EpiLife
Defined Growth Supplement for human primary keratinocytes
culture were purchased from Cascade Biologics Inc. (Portland,
OR). The Amplex Red reagent kit for measuring hydrogen peroxide
was purchased from Invitrogen (Carlsbad, CA). N-acetyl-cysteine,
rapamycin, taurine, and 2070-dichlorofluorescein diacetate (DCF-
DA) were purchased from Sigma-Aldrich (St Louis, MO). Antibodies
to IkBa and NF-kB p65 were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA). Anti-catalase antibodies were
generated under contract by our laboratory. Anti-tubulin antibodies
were kindly provided by Dr Raymond Mattingly (Department of
Pharmacology, Wayne State University School of Medicine).
Transducible catalase-SKL: plasmid preparation and enzyme
purification
A transducible form of the human antioxidant enzyme, catalase, was
created by adding a cell-penetrating peptide, specifically nine
arginine residues, to the protein’s amino terminus. To accomplish
this, a double-stranded oligonucleotide encoding nine arginine
residues was produced by annealing a pair of synthesized
complementary oligonucleotides (Operon Biotechnologies Inc.,
Huntsville, AL) flanked by restriction enzyme sites. The oligonucleo-
tides were (top strand) 50-tatgCGCCGTCGCCGTCGCCGTCGCCG
TCGCctgca-30 and (bottom strand) 50-gGCGACGGCGACGGCGAC
GGCGACGGCGca-30. An NdeI restriction site (lowercase letters) is
encoded at the upstream end, whereas a PstI site is at the
downstream end of the double-stranded oligonucleotides. The
double-stranded oligonucleotide was directly ligated into NdeI–P-
stI-digested pQE-2 (Qiagen, Chatsworth, CA).
In addition, the enzyme’s carboxy-terminal peroxisomal targeting
signal 1 was altered from the naturally occurring alanine–asparagi-
ne–leucine to the more efficient serine–lysine–leucine (SKL). To
generate this plasmid, the human catalase gene was PCR amplified
from a full-length cDNA clone (Invitrogen, Paisley, UK). The forward
primer, 50-AAActgcagATGGCTGACAGCCGGGATCCCGCC-30, com-
plemented the amino-terminal sequence of human catalase
along with a PstI restriction site (lowercase letters). The reverse
primer was designed to produce the SKL amino-acid sequence
(50-GGGCGCaagcttTCACAGTTTCGATTTCTCCCTTGCCGCCAAGT-30).
A HindIII restriction site (lowercase letters) was also incorporated
downstream of the stop codon.
The catalase-SKL gene amplified by PCR was digested appro-
priately, and ligated into the pQE-2 vector containing the sequence
encoding the nine arginine residues. Ligation products were
transformed into the E. coli strain DH5a, and the recovered plasmids
were confirmed to be correct by restriction analysis and DNA
sequencing. The sequence-verified (His)6-tagged cell-penetrating
catalase-SKL construct was then expressed in the E. coli strain
Rosetta 2 (DE3)pLysS (Novagen, Madison, WI), according to the
manufacturer’s instructions.
Recombinant catalase protein was purified using a modified
denaturing protocol. To prepare denatured fusion proteins, the
induced cells were harvested and lysed by freeze/thawing in a
binding buffer (5mM imidazole, 500mM NaCl, and 20mM Tris-HCl,
pH 7.9) containing 2M urea. After the removal of the cell debris by
centrifugation, the clarified cell extracts were loaded onto a Ni-NTA
column. The column was washed first with the binding buffer
containing 2M urea and then with a wash buffer (30mM imidazole,
500mM NaCl, and 20mM Tris-HCl, pH 7.9). The proteins were
released by an elution buffer (500mM imidazole, 500mM NaCl, and
20mM Tris-HCl, pH 7.9), followed by desalting with a PD10 column.
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The purified transducible recombinant catalase fusion protein
(in PBS containing 20% glycerol) was then aliquoted and stored
at 80 1C.
Primary human keratinocyte isolation from neonatal foreskin
Neonatal foreskins from healthy males were the source of primary
human keratinocytes. They were obtained through an Internal
Review Board protocol approved by the Human Investigative
Committee at the Wayne State University School of Medicine. Skin
samples were obtained and pooled together from three or more
surgically circumcised foreskins. Isolation of keratinocytes was
performed essentially as described by Liu and Karasek (1978).
Briefly, skin samples were washed, cut, scraped, and treated with a
dispase solution to prepare a largely epidermal layer. The tissue was
then trypsinized, filtered, centrifuged, and the resultant keratinocytes
cultured and seeded as required. The cells were incubated at 37 1C
in a humidified atmosphere of 5% CO2 in a serum-free low-Ca
2þ
(0.06mM) EpiLife keratinocyte growth medium (Cascade Biologics
Inc.) supplemented with bovine hydrocortisone, insulin, pituitary
extract, and transferrin, as well as recombinant human epidermal
growth factor (Cascade Biologics Inc.). The medium was changed
every other day. For all experiments, cells were seeded at passage
numbers 3–5 into 60mm dishes (2 106 cells per well), 24-well
plates (5 105 cells per well), or 96-well plates (1 105 cells per
well), and were treated upon reaching 80–90% confluence. In
experiments designed to examine effects of TNF-a, cells were grown
in standard medium without growth factors for 24 hours to avoid the
effects of supplements in the growth medium and to obtain quiescent
cells with low levels of activated NF-kB.
Measurement of intracellular hydrogen peroxide/ROS
Production of intracellular hydrogen peroxide was determined using
either DCF-DA (Bass et al., 1983; LeBel et al., 1992; Ohba et al.,
1994) or the Amplex Red reagent (Molecular Probes/Invitrogen,
Carlsbad, CA). The method employed in a given experiment is
indicated in the accompanying figure legend.
With the DCF-DA assay, the medium was removed from cells,
which were then washed and incubated with 50 mM DCF-DA in
keratinocyte growth medium at 37 1C for 30minutes. The DCF-DA
was then removed and the cells were washed once again. A
fluorescence microplate reader was used to take a time zero (Ft0)
point at an emission wavelength of 535 nm and an excitation
wavelength of 490 nm. Immediately thereafter, the cells were
subjected to TNF-a treatment with or without pretreatment with
rapamycin, catalase, taurine, or N-acetyl-cysteine in keratinocyte
growth medium, and a time course was initiated. At each time point,
the fluorescence intensity was again determined. For data analysis,
the percentage increase in fluorescence per well was calculated by
the formula [(FtxFt0)/Ft0100], where Ftx is fluorescence at time x
minutes and Ft0 is fluorescence at time 0minute.
Measurement of intracellular hydrogen peroxide was also
directly determined using Amplex Red hydrogen peroxide/perox-
idase assay kit. The principle behind this assay is that Amplex Red is
a derivative of 10-acetyl-3,7-dihydroxyphenoxazine, which be-
comes highly fluorescent upon oxidation by hydrogen peroxide in
the presence of horseradish peroxidase. Experimentally, after a given
treatment, equal numbers of cells were washed twice with PBS (pH
7.4) and harvested into reaction buffer containing the Amplex Red
reagent for 30minutes, according to the manufacturer’s protocol.
Fluorescence was recorded in a microplate reader (Molecular
Devices, Sunnyvale, CA) set at 530 nm excitation and 590 nm
emission wavelengths.
Cytokine mRNA expression determined by real-time
quantitative RT-PCR
At the end of a particular treatment, human primary keratinocyte
samples were harvested, treated with lysis buffer, and total RNA was
extracted according to the RNeasy Mini Kit manual (Qiagen). RNA
concentrations and 260/280 ratios were assessed using a DU530
spectrophotometer (Beckman, Fullerton, CA). Reverse transcription
of cDNA was performed using random hexamers as primers
according to the SuperScript II Reverse Transcriptase System
Reagents kit manual (Invitrogen, Carlsbad, CA).
To assess the relative transcript levels of specific genes, the cDNA
products were subjected to real-time SYBR-green-based quantitative
PCR as described by Lee et al. (2006). The primers used for these
studies were generated from GenBank (http://www.ncbi.nlm.nih.
gov/Genbank; provided in the public domain by the National Center
for Biotechnology Information, Bethesda, MD) with Gene Runner
software (Hastings Software, Hastings, NY). Primer sequences used
were as indicated in Table 1. We confirmed that primers amplified
the appropriate products by testing under real-time PCR conditions.
Each assay typically was repeated twice, with each sample run in
triplicate. Signals from each sample were normalized to values
Table 1. Primer sequences for real-time PCR
Gene Primer Sequence Product size (bp)
TNF-a Sense 50-CTACTCCCAGGTTCTCTTCAA-30 137
TNF-a Antisense 50-GCAGAGAGGAGGTTGACTTTC-30
IL-6 Sense 50-ATGAACTCCTTCTCCACAAGC-30 156
IL-6 Antisense 50-CTACATTTGCCGAAGAGCCCCTG-30
IL-8 Sense 50-ATCAAGGCGCATGTGAACTC-30 140
IL-8 Antisense 50-AGAGCCCCAGATCCGATTTT-30
18S rRNA Sense 50-CGGCTACCACATCCAAGGAA-30 178
18S rRNA Antisense 50-GCTGGAATTACCGCGGCT-30
TNF-a, tumor necrosis factor-a.
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obtained for the 18S rRNA gene, which was run as a ‘‘housekeeping
gene’’ simultaneously with the experimental samples. Cycle thresh-
old numbers (Ct) were recorded from the exponential phase of PCR
amplification. The relative expression of cytokine mRNA was
calculated using the comparative 2-DDCt method, as previously
described (Livak and Schmittgen, 2001). The results from each run
for each sample were averaged and expressed as the relative level of
the mRNA transcript.
Detection of NF-jB activation by western blot analysis
After human primary keratinocytes were incubated under the
appropriate experimental conditions, cells were harvested in 2
SDS-PAGE sample buffer and subjected to western blot analysis.
Briefly, equal amounts of whole-cell extracts were resolved by 10%
SDS-PAGE and transferred onto a nitrocellulose membrane. After
nonspecific binding sites were quenched using blocking buffer (5%
non-fat dry milk, 0.5% Tween-20 in 20mM Tris-buffered saline, pH
7.6), the membrane was incubated overnight with primary anti-
bodies specific for IkBa or tubulin. The anti-IkBa antibodies were
used at a 1:500 dilution, and the anti-tubulin antibodies were used at
a 1:200 dilution. The blot was washed and incubated again with
horseradish peroxidase-conjugated anti-goat or anti-rabbit IgG
secondary antibodies. After washing once again, protein levels were
determined by chemiluminescence using an ECL detection system.
The intensities of the bands were measured using a Fujifilm
LAS1000plus luminescent image analyzer.
NF-jB p65 subunit translocation detected by indirect
immunofluorescence confocal microscopy
Human keratinocytes grown on glass coverslips were fixed with 4%
(w/v) formaldehyde for 10minutes and permeabilized in 1% (v/v)
Triton X-100 for 5minutes. The cells were blocked with 4% (w/v)
BSA for 1 hour and then incubated with primary antibodies for 1 hour
and secondary antibodies for 45minutes. All reactions were
conducted in PBS; rabbit anti-p65 antibodies were used at a 1:500
dilution and CY3-conjugated goat anti-rabbit secondary antibodies
were used at a 1:250 dilution. Coverslips were mounted in PBS
containing anti-fade mounting media and examined using a confocal
fluorescence microscope (Zeiss LSM510) at the Core Facility,
Department of Pharmacology, Wayne State University School of
Medicine.
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